Ellerston India Fund

Monthly Report as at 30 September 2025

APIR Code: ECL0339AU | ARSN 618 549 796

Portfolio of 20-50 Indian Companies built through a distinctive high growth, high conviction, and benchmark independent investment approach.

Targets companies which offer attractive risk/reward profiles, utilizing 'bottom up' analysis, along with a 'top down' analysis of macroeconomic conditions and structural themes.

Aims to outperform the Benchmark with a focus on capital growth and downside protection.

Strategy Performance Summary

Period	1 Month	3 Months	1 Year	3 Years (p.a.)	5 Years (p.a.)	Since Inception^^ (p.a.)
Gross Return Before Tax+	-0.8%	-6.1%	-5.3%	13.5%	14.2%	10.7%
Benchmark**	-0.7%	-8.6%	-9.1%	9.2%	14.9%	10.2%
Strategy Relative Performance	-0.1%	2.5%	3.8%	4.3%	-0.7%	0.5%

+ Strategy performance before taking into account fees, costs and applicable capital gains taxes. Past performance is not a reliable indication of future performance.
*** Benchmark is MSCI India Net Return Index (AUD) and does not take into account capital gains taxes.*
^^ Inception date is 4 May 2017

Investor Performance Summary

Period	1 Month	3 Months	1 Year	3 Years (p.a.)	5 Years (p.a.)	Since Inception^^ (p.a.)
Net Return After Tax^	-0.9%	-6.4%	-5.2%	10.2%	11.3%	8.5%
Benchmark**	-0.7%	-8.6%	-9.1%	9.2%	14.9%	10.2%
Investor Relative Performance	-0.2%	2.2%	3.9%	1.0%	-3.6%	-1.7%

^Fund return is calculated after taking into account management fees and expenses as well as capital gains taxes on unrealised gains/losses. This return is based on the NAV calculation and reflects the return received by investors in the Fund. Past performance is not a reliable indication of future performance.
*** Benchmark is MSCI India Net Return Index (AUD) and does not take into account capital gains taxes.*
^^ Inception date is 4 May 2017

Key Information

Investment Objective	To outperform the Benchmark on a net of fees and tax basis, with a focus on capital growth and downside protection.
Benchmark	MSCI India Net Return Index (AUD)
Liquidity	Daily
Target Number of Holdings	20-50
Minimum Investment	Initial investment - $10,000 Additional investment - $5,000
Distribution Frequency	Half-Yearly (where available)
Management Fee	1.10% p.a.
Performance Fee[1]	15.00%
Buy/Sell Spread	0.25% / 0.25%
Unit Prices	Application – $ 0.9605 Net Asset Value – $0.9581 Redemption – $ 0.9557

[1]Of the investment return above the benchmark, after recovering any underperformance in past periods.

Top Holdings*

Company	Sector
Aptus Value Housing Finance	Financials
Axis Bank	Financials
One 97 Communications	Financials
OneSource Specialty Pharma	Health Care
Rainbow Children's Medicare	Health Care

**In alphabetical order*
Source: Ellerston Capital

Sector Allocation



Source: Ellerston Capital

MARKET COMMENTARY

The Ellerston India Fund (EIF) returned -0.92% (net) in September, versus the MSCI India Index (MXIN) which returned -0.75% (MXIN was up 1.15% in INR terms). MXIN in local currency was marginally positive, balancing the tailwinds of GST reforms and festive demand with the headwinds of a US trade deal and the H1B visa fee hike. MXIN significantly trailed MSCI Emerging Markets which was up 7.1% (in USD), with North Asia recording massive inflows from Foreign Institutional Investors (FIIs), driven by China's reform/policy/stimulus/AI play, alongside Taiwan and South Korea benefitting from AI/advanced-chip optimism. In India, FIIs were net sellers in September to the tune of USD$2.2bn (secondary). Domestic Institutional Investors (DIIs) remained net buyers to the tune of USD$7.4bn.

The USD$100k hike in H1B visa fees, if implemented, will increase cost of doing business for both IT service companies and their end-clients. This also led to a new low in the USD/INR pair, amidst concerns around remittances & service exports.

KEY MONTHLY CONTRIBUTOR

Not Owning ICICI Bank and owning Dr. Agarwal Healthcare were the key performance attributors for the month. Dr Agarwal is the largest eye care hospital chain in India, with ~65% surgical sales mix. It has a market share of ~25% within the organized space which is only ~15% of the overall market. Latent demand for eye care remains strong and highly under-penetrated, with Dr. Agarwal executing a solid expansion plan via both organic and inorganic means. In September, the company merged its smaller Dr. Agarwal's Eye Hospital listed stock into Dr. Agarwal's Health Care and started trading on a consolidated basis. The company also published an updated investor deck in late August.

KEY MONTHLY DETRACTOR

Rainbow Children's Medicare was impacted by increased FII selling as the market rotated away from defensive hospital stocks. Rainbow is one of the largest paediatric hospital chains in India with 10% market share. It has a premium positioning given its higher focus on neonatal and paediatric Intensive Care Units. Rainbow Children's Medicare launched a 100-bed hospital in Rajahmundry, Andhra Pradesh in September. Typically, the current quarter is a seasonally weak quarter in the paediatric category which can have a near-term impact on stock price.

OUTLOOK

India is trudging through a short-term period of weaker economic and earnings growth within its longer-term trend of superior relative growth. Expected earnings are expected to move back to stronger growth trajectory from H2FY26 driven by good monsoons, GST reduction, better festive season and easing geopolitical tensions. September GST collections were up by 9.1% year-on-year and credit growth was also weak at 9.5% year-on-year. Disinflation is underway with CPI falling to 1.54% in Sept (2.07% in Aug), the lowest since 2017, driven by lower food inflation with vegetables and edible oils inflation declining. October trends point to a further drop in inflation. RBI (Reserve Bank of India) left the Repo Rate unchanged at 5.50% and stance at neutral, but there is space for monetary easing in December policy with further rate cuts over the next 6 to 12 months.

As always, if you have any questions regarding any aspect of the Fund or the portfolio, please feel free to contact us at info@ellerstoncapital.com.

Regulatory Guide (RG240) Fund Disclosure Benchmark – Periodic Reporting (monthly)

- **Net Asset Value of the Fund and Redemption Price of Units**
  Please refer to details on page one.

- **Any changes to key service providers including any change in related party status**
  There have been no changes to key service providers, including any change in related party status.

- **Net returns after fees, costs and relevant taxes**
  Please refer to details on page one.

- **Any material changes to the Fund's risk profile and strategy**
  There have been no changes to the Fund's risk profile and strategy.

- **Any material changes related to the primary investment personnel responsible for managing the Fund**
  There have been no changes to the primary investment personnel responsible for managing the Fund.

Contact Us

Sydney

Level 11, 179 Elizabeth Street,
Sydney, NSW 2000
+612 9021 7701
info@ellerstoncapital.com

Find out more:

Should investors have any questions or queries regarding the Fund, please contact our Investor Relations team on 02 9021 7701 or info@ellerstoncapital.com or visit us at ellerstoncapital.com.

All holding enquiries should be directed to our registry, Automic Group on 1300 101 595 or ellerstonfunds@automicgroup.com.au.

Ellerston Capital